 <h1>Doxorubicin Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of doxorubicin include:</b> severe nausea and vomiting, nausea and vomiting, and alopecia.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to doxorubicin: intravenous powder for solution, intravenous solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Intravenous route (Solution; Powder for Solution)</p><p>Myocardial damage can occur with DOXOrubicin hydrochloride with incidences from 1% to 20% for cumulative doses from 300 to 500 mg/m(2) when DOXOrubicin hydrochloride is administered every 3 weeks. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess left ventricular ejection fraction (LVEF) before and regularly during and after treatment with DOXOrubicin hydrochloride. Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including DOXOrubicin hydrochloride. Extravasation of DOXOrubicin hydrochloride can result in severe local tissue injury and necrosis requiring wide excision and skin grafting. Immediately terminate the drug, and apply ice to the affected area. Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, doxorubicin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking doxorubicin:</p><p>
<i>Less common</i>
</p><ul>
<li>Cough or hoarseness accompanied by fever or chills</li>
<li>darkening or redness of the skin (if you recently had radiation treatment)</li>
<li>fast or irregular heartbeat</li>
<li>fever or chills</li>
<li>joint pain</li>
<li>lower back or side pain accompanied by fever or chills</li>
<li>pain at the injection site</li>
<li>painful or difficult urination accompanied by fever or chills</li>
<li>red streaks along the injected vein </li>
<li>shortness of breath</li>
<li>stomach pain</li>
<li>swelling of the feet and lower legs</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Black, tarry stools</li>
<li>blood in the urine</li>
<li>pinpoint red spots on the skin</li>
<li>unusual bleeding or bruising</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of doxorubicin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Hair loss, thinning of hair</li>
<li>nausea and vomiting</li>
<li>sores in the mouth and on the lips</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Darkening of the soles, palms, or nails</li>
<li>diarrhea</li>
</ul><p>After you stop using this medicine, it may still produce some side effects that need attention. During this period of time, <b>Check with your doctor immediately</b> if you notice the following side effects:</p><ul>
<li>Fast or irregular heartbeat</li>
<li>shortness of breath</li>
<li>swelling of the feet and lower legs</li>
</ul><p>
<!-- end intravenous powder for solution, intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to doxorubicin: compounding powder, intravenous powder for injection, intravenous solution</i></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Cardiomyopathy, decreased LVEF, ECG changes (e.g., sinus tachycardia, tachyarrhythmia, ventricular tachycardia, bradycardia, bundle branch block), congestive heart failure</p>
<p><b>Very rare</b> (less than 0.01%): Pericarditis, myocarditis</p>
<p><b>Postmarketing reports</b>: Cardiogenic shock, phlebosclerosis, phlebitis/thrombophlebitis, hot flashes, thromboembolism<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Leucopenia (60% to 80%)</p>
<p><b>Common</b> (1% to 10%): Bone marrow suppression</p>
<p><b>Uncommon</b> (0.1% to 1%): Thrombocytopenia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Alopecia</p>
<p><b>Rare</b> (less than 0.1%): Urticaria, exanthema, local erythematous reactions along the vein which was used for the injection, hyperpigmentation of skin and nails, onycholysis </p>
<p><b>Postmarketing reports</b>: Oncolysis, rash, itching, photosensitivity, urticaria, acral erythema, palmar plantar erythrodysesthesia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea and vomiting (20% to 85%), stomatitis (up to 80%), diarrhea (12%)</p>
<p><b>Common</b> (1% to 10%): Mucositis</p>
<p><b>Uncommon</b> (0.1% to 1%): Ulceration and necrosis of the colon, especially the cecum (in combination with cytarabine)<sup>[Ref]</sup></p><h3>Local</h3><p><b>Frequency not reported</b>: Extravasation, tissue necrosis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (0.01% to 0.1%): Anaphylactic reactions<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Rare</b> (0.01% to 0.1%): Renal insufficiency<sup>[Ref]</sup></p><h3>Other</h3><p><b>Rare</b> (0.01% to 0.1%): Shivering, fever </p>
<p><b>Frequency not reported</b>: Radiation recall</p>
<p><b>Postmarketing reports</b>: Malaise, asthenia, fever, chills<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Secondary malignancies<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Rare</b> (0.01% to 0.1%): Conjunctivitis </p>
<p><b>Postmarketing reports</b>: Keratitis, lacrimation<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Local reactions (chemical cystitis) may occur with intravesical treatment</p>
<p><b>Rare</b> (less than 0.1%): Bladder contracture </p>
<p><b>Frequency not reported</b>: Amenorrhea<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Anorexia</p>
<p><b>Frequency not reported</b>: Hyperuricemia, tumor lysis syndrome</p>
<p><b>Postmarketing reports</b>: Weight gain<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Postmarketing reports</b>: Increased alanine aminotransferase, increased aspartate aminotransferase<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Dyspnea</p>
<p><b>Frequency not reported</b>: Bronchospasm, cough, epistaxis, pneumonia, nasopharyngitis, upper respiratory tract infection<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Rare</b> (0.01% to 0.1%): Dizziness </p>
<p><b>Postmarketing reports</b>: Peripheral sensory and motor neuropathy, seizures, coma<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn, Kalamazoo, MI. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What is the lifetime or cumulative dose for Adriamycin?</li>
<li>How does AC (Adriamycin and Cytoxan [cyclophosphamide]) work for Breast Cancer?</li>
<li>What are the long-term side effects of Adriamycin?</li>
<li>Does Adriamycin cause heart failure?</li>
<li>How is Lartruvo administered?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about doxorubicin</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>9 Reviews</li>
<li>Drug class: antibiotics/antineoplastics</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Doxorubicin Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Adriamycin</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +3 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Breast Cancer</li>
<li>Acute Lymphoblastic Leukemia</li>
<li>Acute Myeloblastic Leukemia</li>
<li>Bladder Cancer</li>
<li data-more-config-id="list-data-resources-conditions">... +14 more</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to doxorubicin: compounding powder, intravenous powder for injection, intravenous solution</i></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Cardiomyopathy, decreased LVEF, ECG changes (e.g., sinus tachycardia, tachyarrhythmia, ventricular tachycardia, bradycardia, bundle branch block), congestive heart failure</p><p><b>Very rare</b> (less than 0.01%): Pericarditis, myocarditis</p><p><b>Postmarketing reports</b>: Cardiogenic shock, phlebosclerosis, phlebitis/thrombophlebitis, hot flashes, thromboembolism<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Leucopenia (60% to 80%)</p><p><b>Common</b> (1% to 10%): Bone marrow suppression</p><p><b>Uncommon</b> (0.1% to 1%): Thrombocytopenia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Alopecia</p><p><b>Rare</b> (less than 0.1%): Urticaria, exanthema, local erythematous reactions along the vein which was used for the injection, hyperpigmentation of skin and nails, onycholysis </p><p><b>Postmarketing reports</b>: Oncolysis, rash, itching, photosensitivity, urticaria, acral erythema, palmar plantar erythrodysesthesia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea and vomiting (20% to 85%), stomatitis (up to 80%), diarrhea (12%)</p><p><b>Common</b> (1% to 10%): Mucositis</p><p><b>Uncommon</b> (0.1% to 1%): Ulceration and necrosis of the colon, especially the cecum (in combination with cytarabine)<sup>[Ref]</sup></p><h3>Local</h3><p><b>Frequency not reported</b>: Extravasation, tissue necrosis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (0.01% to 0.1%): Anaphylactic reactions<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Rare</b> (0.01% to 0.1%): Renal insufficiency<sup>[Ref]</sup></p><h3>Other</h3><p><b>Rare</b> (0.01% to 0.1%): Shivering, fever </p><p><b>Frequency not reported</b>: Radiation recall</p><p><b>Postmarketing reports</b>: Malaise, asthenia, fever, chills<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Secondary malignancies<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Rare</b> (0.01% to 0.1%): Conjunctivitis </p><p><b>Postmarketing reports</b>: Keratitis, lacrimation<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Local reactions (chemical cystitis) may occur with intravesical treatment</p><p><b>Rare</b> (less than 0.1%): Bladder contracture </p><p><b>Frequency not reported</b>: Amenorrhea<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Anorexia</p><p><b>Frequency not reported</b>: Hyperuricemia, tumor lysis syndrome</p><p><b>Postmarketing reports</b>: Weight gain<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Postmarketing reports</b>: Increased alanine aminotransferase, increased aspartate aminotransferase<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Dyspnea</p><p><b>Frequency not reported</b>: Bronchospasm, cough, epistaxis, pneumonia, nasopharyngitis, upper respiratory tract infection<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Rare</b> (0.01% to 0.1%): Dizziness </p><p><b>Postmarketing reports</b>: Peripheral sensory and motor neuropathy, seizures, coma<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn, Kalamazoo, MI. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What is the lifetime or cumulative dose for Adriamycin?</li>
<li>How does AC (Adriamycin and Cytoxan [cyclophosphamide]) work for Breast Cancer?</li>
<li>What are the long-term side effects of Adriamycin?</li>
<li>Does Adriamycin cause heart failure?</li>
<li>How is Lartruvo administered?</li>
</ul><h2>More about doxorubicin</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>9 Reviews</li>
<li>Drug class: antibiotics/antineoplastics</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Doxorubicin Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +3 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Breast Cancer</li>
<li>Acute Lymphoblastic Leukemia</li>
<li>Acute Myeloblastic Leukemia</li>
<li>Bladder Cancer</li>
<li data-more-config-id="list-data-resources-conditions">... +14 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>